EBC - Discussions

ENG

FLEX (MammaPrint)

ASCO 2024

The search for predicitve biomarkers continues

F. Cardoso, V. Diéras, K. Gelmon, V. Guarneri, C. Criscitiello

ENG

A-BRAVE, PEARLY

ASCO 2024

Immunotherapy makes a difference in survival in eTNBC

F. Cardoso, V. Diéras, A. Gennari, K. Gelmon, V. Guarneri, C. Criscitiello

ENG

monarchE, ER-low

ASCO 2024

Prognostic value of ctDNA in therapeutic strategies;…

F. Cardoso, V. Diéras, A. Gennari, K. Gelmon, V. Guarneri, C. Criscitiello

EBC - 100 sec

ENG

ASCO 2024

Adjuvant endocrine therapy for ER-low EBC

Andreas Schneeweiss, MD

ENG

I-SPY2.2

ASCO 2024

Personalized neoadjuvant therapy for high-risk breast…

Hope Rugo, MD

ENG

A-BRAVE

ASCO 2024

Avelumab in early TNBC

Valentina Guarneri, MD, PhD

ENG

ASCO 2024

AI for the prediction of disease progression

Nadia Harbeck, MD

EBC - CDK4/6i 100 sec

ENG

monarchE

ASCO 2024

ctDNA analysis in monarchE

Wolfgang Janni, MD

ENG

NATALEE

ASCO 2024

Advantage for node-negative patients

Michael Untch, MD

ENG

monarchE

ASCO 2024

ctDNA important for HR+ eBC?

Peter A. Fasching, MD

ENG

NATALEE

ASCO 2024

Ribociclib is also effective in N0 HR+/HER2− EBC

Andreas Schneeweiss, MD

EBC - 100 sec multi language

ITA

A-BRAVE

ASCO 2024

Avelumab nel TNBC precoce

Valentina Guarneri, MD, PhD

ABC - Discussions

ENG

Young-PEARL, Post Monarch

ASCO 2024

Reassuring and clarifying new data for CDK4/6…

D. Lüftner, E. Senkus, N. Harbeck, V. Guarneri, B. Pistilli, M. Untch

ENG

INAVO120

ASCO 2024

Improvement for firstline treatment for patients with…

A. Schneeweiss, V. Guarneri, V. Diéras, H. Rugo, A. Gennari, N. Harbeck

ENG

Destiny-Breast06

ASCO 2024

Expanding T-DxD use to HER2 ultra-low - the success…

D. Lüftner, G. Curigliano, R. Dent, H. Rugo, W. Janni

ENG

PATRICIA

ASCO 2204

One step closer to chemo-free therapy for HR+/HER2+…

V. Müller, E. Senkus, V. Diéras, A. Gennari, B. Pistilli, P. Fasching

ABC - 100 sec

ENG

EMERALD

ASCO 2024

Eribulin, Trastuzumab, Pertuzumab in 1stL HER2+ mBC

Diana Lüftner, MD

ENG

PATRICIA

ASCO 2024

Triple positive mBC - chemotherapy unnecessary?

Wolfgang Janni, MD

ENG

PATRICIA

ASCO 2024

Is there still a place for endocrine therapy in HER2+…

Barbara Pistilli, MD

ENG

TBCRC049

ASCO 2024

Leptomeningeal metastases in HER2+ mBC

Volkmar Müller, MD

ENG

ASCO 2024

ER-low: endocrine therapy necessary after all?

Volkmar Müller, MD

ENG

DE-REAL

ASCO 2024

Systemic therapy of HER2+ patients with brain…

Volkmar Müller, MD

ENG

Young-PEARL

ASCO 2024

New data on the omission of chemotherapy in young…

Wolfgang Janni, MD

ENG

RxPONDER

ASCO 2024

Responder premenopausal

Peter A. Fasching, MD

ENG

ASCO 2024

Heterogenity of ER+ disease

Hope Rugo, MD

ABC - ADC 100 Sec

ENG

SACI-IO HR+

ASCO 2024

Novel ADC-ICI combination therapy

Sara Tolaney, MD

ENG

DESTINY-Breast07

ASCO 2024

HER2+ mBC 1stL T-Dxd

Diana Lüfner, MD

ENG

OptiTROP-Breast01

ASCO 2024

Sacituzumab tirumotecan - a new powerful ADC for…

Elzbieta Senkus-Konefka, MD

ENG

Destiny-Breast 06

ASCO 2024

Broaden T-DXD as therapy standard for HER2low and…

Sara Tolaney, MD

ENG

Destiny-Breast06

ASCO 2024

Expanding use of T-DxD in HER2low and HER2 ultra-low…

Giuseppe Curigliano, MD

ENG

Destiny Breast 03

ASCO 2024

Important OS benefit with T-Dxd in HER2+ mBC

Javier Cortés, MD, PhD

ENG

Destiny-Breast07

ASCO 2024

T-DXD continues its impressive track record for MBC…

Hope Rugo, MD

ENG

DESTINY-Breast06

ASCO 2024

Ultra low - ultra good?

Wolfgang Janni, MD

ENG

ADC - Clinical Science Symposium

ASCO 2024

The ADC revolution continues - ctDNA takes the next…

Veronique Dieras, MD

ENG

PRIMED

ASCO 2024

Decreasing SG related toxicity with profilatic G-CFS

Javier Cortés, MD, PhD

ABC - CDK4/6i - 100 sec

ENG

Young-PEARL

ASCO 2024

CDK4/6i effective in premenopausal patients as well

Andreas Schneeweiss, MD

ENG

PATRICIA

ASCO 2024

Chemo-free regimen in HER2+ luminal breast cancer

Alessandra Gennari, MD, PhD

ENG

INAVO120

ASCO 2024

First-line inavolisib/placebo + palbociclib +…

Andreas Schneeweiss, MD

ENG

postMONARCH

ASCO 2024

Treatment beyond progression for CDK 4/6i

Andreas Schneeweiss, MD

ENG

PATRICIA

ASCO 2024

Chemo-free, CDK4/6 inhibitor-based combination active…

Elzbieta Senkus-Konefka, MD

ENG

INAVO120

ASCO 2024

Already more in the 1stL?

Wolfgang Janni, MD

ENG

PATRICIA

ASCO 2024

Endocrine therapy with Palbociclib + Trastuzumab

Diana Lüftner, MD

ENG

postMonarch

ASCO 2024

CDK4/6 rechallenge

Alessandra Gennari, MD, PhD

ENG

INAVO120

ASCO 2024

INAVO120 - updated results

Valentina Guarneri, MD, PhD

ABC - 100 sec multi language

POL

OptiTROP-Breast01

ASCO 2024

Sacituzumab tirumotecan – nowy aktywny koniugat w…

Elzbieta Senkus-Konefka, MD

ESP

Destiny Breast 03

ASCO 2024

Importante beneficio en la supervivencia global con…

Javier Cortés, MD, PhD

ESP

PRIMED

ASCO 2024

Disminución de la toxicidad relacionada con la OS con…

Javier Cortés, MD, PhD

ITA

PATRICIA

ASCO 2024

C'è ancora posto per la terapia endocrina nel BC HER2+?

Barbara Pistilli, MD

ITA

PATRICIA

ASCO 2024

Regime senza chemioterapia nel carcinoma mammario…

Alessandra Gennari, MD, PhD

ITA

INAVO120

ASCO 2024

INAVO120: risultati aggiornati

Valentina Guarneri, MD, PhD

POL

PATRICIA

ASCO 2024

Leczenie bez chemioterapii, oparte na inhibitorze…

Elzbieta Senkus-Konefka, MD

ITA

postMonarch

ASCO 2024

CDK4/6 rechallenge

Alessandra Gennari, MD, PhD

FRA

ASCO 2024

La révolution de l'ADC se poursuit / ctDNA franchit une…

Véronique Diéras, MD

FRA

PATRICIA

ASCO 2024

Le traitement endocrinien a-t-il encore sa place dans…

Barbara Pistilli, MD

ITA

Destiny-Breast06

ASCO 2024

Espansione dell'uso di T-DxD nelle pazienti con…

Giuseppe Curigliano, MD

PCa - Discussions

ENG

PROMISE

ASCO 2024

PSMA-PET CT: Ready for clinical practice or a PROMISE…

A. Bartjell, S. Chowdhury, N. Shore, A. Merseburger, G. Morgan

ENG

MAST, MANCAN

ASCO 2024

Is the metformin story over? How to treat HFNS…

M.-O. Grimm, A. Bjartell, S. Chowdhury, E. Efstathiou

ENG

EMBARK, PRESTO

ASCO 2024

Focus on Quality of Life

A. Merseburger, G. Morgan, A. Bjartell, S. Chowdhury, N. Shore, E. Efstathiou, Y. Loriot

ENG

CHAARTED2, CYCLONE 2, PSMAfore

ASCO 2024

Interesting data - but not practice changing

Y. Loriot, M.-O. Grimm, G. Morgan, S. Chowdhury, N. Shore, E. Efstathiou

PCa - 100 sec

ENG

COBRA

ASCO 2024

The evolving role of PSMA-PET with new agents

Neal Shore, MD

ENG

JNJ-6420

ASCO 2024

Radionukleotides - the next step forward

Simon Chowdhury, PhD

ENG

PSMA-fore

ASCO 2024

RCT in mCRPC

Axel S. Merseburger, MD

ENG

PSMAfore

ASCO 2024

Important QoL data

Simon Chowdhury, PhD

ENG

CYCLONE 2

ASCO 2024

mCRCP CYCLONE 2 study

Axel S. Merseburger, MD

ENG

EMBARK

ASCO 2024

EMBARK: Quality of Life

Axel S. Merseburger, MD

ENG

PROMISE

ASCO 2024

Unveiling the Potential: PSMA-PET in Prostate Cancer…

Gil Morgan, MD

ENG

ARASENS

ASCO 2024

ARASENS Post hoc analysis: Therapy after progression

Marc-Oliver Grimm, MD

STAMPEDE

ASCO 2024

mCRPC: Who benefits from which measures?

Philipp Ivanyi, MD

ENG

EMBARK

ASCO 2024

EMBARK demonstrates the importance of HRQoL benefit in…

Neal Shore, MD

ENG

ALLIANCE

ASCO 2024

Unlocking Insights: The ALLIANCE Trial redefining…

Gil Morgan, MD

ENG

CHAARTED2

ASCO 2024

Exploring the CHAARTED TRIAL: Optimizing Treatment…

Gil Morgan, MD

ENG

EMBARK

ASCO 2024

Deciphering EMBARK: Exploring Enzalutamide's Impact on…

Gil Morgan, MD

UC - Discussions

Sure 01,02, TROPICS-04

ASCO 2024

Perioperative treamtent in MIBC - new data for the use…

V. Grünwald, T. Powles, I. Duran, Y. Loriot, P. Grivas

ENG

EV-302, EV-101,EV-201,EV-301, Checkmate 901

ASCO 2024

EV-Pembro shows consistent outcome - caution with…

V. Grünwald, T. Powles, I. Duran, Y. Loriot, P. Grivas

UC - 100 sec

ENG

JAVELIN Bladder 100

ASCO 2024

Biomarkers and long-term outcomes in pts with low tumor…

Joaquim Bellmunt, MD

ENG

ASCO 2024

Quality of life not affected by i. v. Pembro

Peter Goebell, MD

ENG

ULTIMA

ASCO 2024

Treatment of urachal carcinoma

Axel S. Merseburger, MD

ENG

SWOG S1600

ASCO 2024

Effect of an immune diet on the outcome after radical…

Peter Goebell, MD

ENG

KEYNOTE-361

ASCO 2024

ctDNA as a biomarker in metastatic bladder cancer

Axel S. Merseburger, MD

ENG

HERCULES

ASCO 2024

ASCO 2024: Time for the rare GU tumors?

Ignacio Duran, MD

ENG

ASCO 2024

MI-UC - News from EVP standard

Philipp Ivanyi, MD

ENG

CheckMate 901

ASCO 2024

What to do with Cis Gem Nivo?

Philipp Ivanyi, MD

UC - 100 sec ADC

ENG

SURE-01/02

ASCO 2024

Interim analysis of the SURE-01/02 study

Axel S. Merseburger, MD

ENG

SURE-01/02

ASCO 2024

The Role of Topoisomerase Inhibitors in the…

Ignacio Duran, MD

ENG

EV-302, EV-201, CheckMate 901, TROPICS-04, SURE-01/02

ASCO 2024

ASCO24: Bladder cancer highlights

Petros Grivas, MD, PhD

ENG

SURE-01/02

ASCO 2024

The future of sacituzumab govitecan

Joaquim Belmunt, MD

UC - 100 sec multi language

ESP

SURE-01/02

ASCO 2024

El futuro de sacituzumab govitecan

Joaquim Bellmunt, MD, PhD

ESP

SURE-01/02

ASCO 2024

El papel de los inhibidores de topoisomerasa en el…

Ignacio Duran, MD

ESP

JAVELIN, Bladder 100

ASCO 2024

Biomarcadores y resultados a largo plazo en pacientes…

Joaquim Bellmunt, MD, PhD

GRE

EV-302, EV-201, CheckMate 901, TROPICS-04, SURE-01/02

ASCO 2024

ASCO24: Bladder cancer highlights

Petros Grivas, MD, PhD

ESP

ASCO 2024

ASCO 2024: momento para los tumores GU poco frequentes?

Ignacio Duran, MD

RCC - Discussions

ENG

CARAT

ASCO 2024

Supportive real-world data from German research…

P. J. Goebell, H. Hammers, B. Rini, V. Grünwald, P. Ivanyi

ENG

ASCO 2024

Evaluating risk criteria and monotherapy in mRCC

V. Grünwald, P. Ivanyi, P. J. Goebell, H. Hammers, B. Rini, T. Powles, S. K. Pal

ENG

KEYNOTE-426, CLEAR

ASCO 2024

Advancing our understanding of biological mechanisms…

V. Grünwald, P. Ivanyi, P. J. Goebell, H. Hammers, B. Rini, J. Bellmunt, T. Powles, S. K. Pal

ENG

IMmotion101

ASCO 2024

Advancing Our Understanding of Biological Mechanisms…

V. Grünwald, P. Ivanyi, P. J. Goebell, H. Hammers, B. Rini, J. Bellmunt, T. Powles, S. K. Pal

ENG

ASCO 2024

Combination is superior to monotherapy - how do we…

S. K. Pal, V. Grünwald, P. J. Goebell, B. Rini, J. Bellmunt, T. Powles

RCC - 100 sec

ENG

ASCO 2024

Metastasized chromophobe RCC

Axel S. Merseburger, MD

ENG

ASCO 2024

nccRCC

Sumanta K. Pal, MD

ENG

IMmotion010

ASCO 2024

KIM-1 - old wine in new bottles

Peter Goebell, MD

ENG

ASCO 2024

DFF332 a novel HIF inhibitor

Sumanta K. Pal, MD

ENG

LITESPARK-013

ASCO 2024

Belzutifan in earlier lines in advanced ccRCC

Hans Hammers, MD, PhD

ENG

IMmotion010

ASCO 2024

Another breakthrough perioperative

Philipp Ivanyi, MD

ENG

IMotion101

ASCO 2024

KIM-1: Will have a major impact

Hans Hammers, MD, PhD

ENG

IMmotion 101

ASCO 2024

Adjuvant KIM-1 as prognostic & predictive biomarker

Brian Rini, MD

ENG

ASCO 2024

New IMDC risk group - very favorable

Axel S. Merseburger, MD

ENG

CLEAR, KEYNOTE426

ASCO 2024

The never ending saga of biomarkers

Hans Hammers, MD, PhD

ENG

KEYNOTE 426, CLEAR

ASCO 2024

Biomarker analysis of KN426 & CLEAR

Brian Rini, MD

ENG

IMDC

ASCO 2024

Treatment of favorable prognosis mRCC patients:…

Ignacio Duran, MD

ENG

KEYNOTE426, CLEAR

ASCO 2024

The search of the ideal biomarker in advanced renal…

Ignacio Duran, MD

ENG

ASCO 2024

New HIF inhibitor in clear cell RCC

Axel S. Merseburger, MD

RCC - 100 sec multi language

ESP

KEYNOTE426, CLEAR

ASCO 2024

La busqueda del marcador ideal en el cancer renal…

Ignacio Duran, MD

ESP

IMDC

ASCO 2024

Tratamiento del cancer renal avanzado de pronostico…

Ignacio Duran, MD

NSCLC early stages - Discussions

ENG

LAURA

ASCO 2024

End of the story in EGFRm disease?

N. Girard, R. Shah, L. Hendricks, A. Addeo, M. Reck, H. Borghaei, F. Griesinger, N. Reguart, S. Liu, M. Thomas, D. Moro-Sibliot

ENG

CheckMate 816, CheckMate 77T, AGEAN

ASCO 2024

Adjuvant therapy: how to identify patients who will…

N. Girard, R. Shah, L. Hendricks, A. Addeo, M. Reck, H. Borghaei, N. Reguart, S. Liu, M. Thomas, D. Moro-Sibliot

NSCLC early stages - 100 sec

ENG

LAURA

ASCO 2024

Stadium III EGFR+: now permanently Osimertinib?!

Michael Thomas, MD

ENG

ADAURA

ASCO 2024

ctDNA predicts outcome in patients treated with…

Sacha Rothschild, MD

ENG

CheckMate, 77T AEGEAN

ASCO 2024

Perioperative chemotherapy and N2 status

Riyaz Shah, MD

ENG

KEYNOTE-799

ASCO 2024

4-year efficacy of Keynote-799 and ctDNA

Martin Reck, MD

ENG

LAURA

ASCO 2024

Gamechanger in EGFR-mutated NSCLC

Denis Moro-Sibilot, MD

ENG

CheckMate 816

ASCO 2024

4y follow-up of CheckMate 816

Nicolas Girard, MD

ENG

AEGEAN

ASCO 2024

Confirmed efficacy of periop IO in N2 R-NSCLC

Martin Reck, MD

ENG

LAURA

ASCO 2024

Osimertinib improves PFS in stage III

Frank Griesinger, MD, PhD

ENG

ctDNA-Lung-DETECT

ASCO 2024

Liquid biopsy in curative situation

Frank Griesinger, MD, PhD

ENG

CheckMate 816

ASCO 2024

CheckMate 816: 4-year update

Riyaz Shah, MD

ENG

LAURA

ASCO 2024

Early change in SOC in EGFR+ LD-NSCLC

Noemi Reguart, MD

NSCLC early stages - 100 sec multi language

FRA

CheckMate 816

ASCO 2024

4y follow-up de CheckMate 816

Nicolas Girard, MD

ESP

LAURA

ASCO 2024

Cambio temprano en el tratamiento estándar del EGFR+…

Noemi Reguart, MD

LAURA

ASCO 2024

Le traitement adjuvant par osimertinib apres CTRT : …

Denis Moro-Sibilot, MD

NSCLC adv/met - Discussions

ENG

KRYSTAL-12, KROCUSn CodeBreaK 101

ASCO 2024

KRAS in NSCLC - a lot to come

S. Liu, D. Moro-Sibilot, M. Reck, R. Shah, A. Addeo, M. Thomas

ENG

CROWN

ASCO 2024

Lorlatinib with extraordinary data in ALK + NSCLC

D. Moro-Sibilot, R. Shah, F. Griesinger, N. Girard, N. Reguart, M. Thomas

ENG

EVOKE-01, ICARUS-LUNG01, OptiTROP-Lung01

ASCO 2024

TROP2-targeting ADCs: where a we heading?

M. Thomas, S. Liu, R. Shah, A. Addeo, N. Girard, N. Reguart

ENG

MARIPOSA, PALOMA-3, HARMONi-A

ASCO 2024

Update for EGFR-positive NSCLC

M. Reck, D. Moro-Sibilot, S. Liu, N. Reguart, A. Addeo, N. Girard

NSCLC adv/met - 100 sec

ENG

MARIPOSA, PALOMA-3

ASCO 2024

EGFR+ NSCLC - amivantamab-based combination therapy

Michael Thomas, MD

ENG

KRYSTAL-12

ASCO 2024

KRASG12C - the story continues

Lizza Hendriks, MD

ENG

CROWN

ASCO 2024

ALK+ NSCLC - CROWN revisited

Michael Thomas, MD

ENG

KRYSTAL-12

ASCO 2024

KRAS building on single agent therapy

Riyaz Shah, MD

ENG

NRG-LU002

ASCO 2024

The end for local therapy for oligometastatic disease

Lizza Hendriks, MD

ENG

KRYSTAL-12

ASCO 2024

Confirmed efficacy of adagrasib in KRASG12C

Martin Reck, MD

ENG

CheckMate 9LA

ASCO 2024

Confirmed efficacy in PD-L1 negativity - CheckMate 9LA

Martin Reck, MD

ENG

KRYSTAL-12

ASCO 2024

Adagrasib for KRASG12C mutation 2nd line

Frank Griesinger, MD, PhD

ENG

PALOMA-3

ASCO 2024

Subcut amivantamab - the future

Riyaz Shah, MD

ENG

ASCO 2024

Telehealth is just as effective as a face-to-face visit…

Denis Moro-Sibiliot, MD

ENG

CROWN

ASCO 2024

Lorlatinib convincing in ALK mutation 1st line

Frank Griesinger, MD, PhD

ENG

EVOKE-01, OptiTROP-Lung01

ASCO 2024

ADCs - moving landscapes. Subgroups remain to be…

Michael Thomas, MD

ENG

ASCO 2024

BAY297088 - Promising Her2-Inhibitor in NSCLC

Nicolas Girard, MD

ENG

LAURA, PALOMA-3, KRYSTAL-12, ADRIATIC

ASCO 2024

ASCO 2024 highlights

Alfredo Addeo, MD

NSCLC adv/met - 100 sec multi language

ASCO 2024

La télésanté est aussi efficace qu'une consultation…

Denis Moro-Sibilot, MD

FRA

ASCO 2024

BAY297088 - Inhibiteur Her2-Inhibitor dans le NSCLC

Nicolas Girard, MD

ITA

LAURA, PALOMA-3, KRYSTAL-12, ADRIATIC

ASCO 2024

ASCO 2024 highlights

Alfredo Addeo, MD

FRA

LAURA, PALOMA-3, KRYSTAL-12, ADRIATIC

ASCO 2024

ASCO 2024 highlights

Alfredo Addeo, MD

NED

KRYSTAL-12

ASCO 2024

KRASG12C - het verhaal gaat verder

Lizza Hendriks, MD

NED

NRG-LU002

ASCO 2024

Het einde van lokale therapie voor oligometastatische…

Lizza Hendriks, MD

SCLC - Discussion

ENG

ADRIATIC

ASCO 2024

Redefining SOC in LD-SCLC: Durvalumab as consolidation…

N. Girard, R. Shah, L. Hendricks, A. Addeo, M. Reck, H. Borghaei, N. Reguart, S. Liu, M. Thomas, D. Moro-Sibliot

SCLC - 100 sec

ADRIATIC

ASCO 2024

Finally, change for LS-SCLC

Lizza Hendriks, MD

ENG

ADRIATIC

ASCO 2024

Maintenance with durvalumab is the new SOC after…

Denis Moro-Sibilot, MD

ENG

DeLLphi-301

ASCO 2024

Tarlatamab shows activity in patients with brain…

Sacha Rothschild, MD

ENG

ADRIATIC

ASCO 2024

New SoC for LD-SCLC

Sacha Rothschild, MD

ADRIATIC

ASCO 2024

LD-SCLC: What´s about PCI?

Michael Thomas, MD

SCLC - 100 sec multi language

ADRIATIC

ASCO 2024

Le traitement d'entretien avec le durvalumab est le…

Denis Moro-Sibilot, MD

NED

ADRIATIC

ASCO 2024

Tot slot, verandering voor LS-SCLC

Lizza Hendriks, MD

Mesothelioma - Discussion

ENG

BEAT-meso

ASCO 2024

Unexpected results; which subgroup could benefit from…

N. Girard, R. Shah, L. Hendricks, A. Addeo, M. Reck, H. Borghaei, N. Reguart, S. Liu, M. Thomas, D. Moro-Sibliot

Mesothelioma - 100 sec

ENG

BEAT-meso

ASCO 2024

Harsh to beat

Noemi Reguart, MD

ENG

BEAT-meso

ASCO 2024

Chemo-immuno in mesothelioma - update

Riyaz Shah, MD

Mesothelioma - 100 sec multi language

ESP

BEAT-meso

ASCO 2024

Difícil de superar

Noemi Reguart, MD

Melanoma - Discussions

ENG

KEYNOTE-942

ASCO 2024

Personalized mRNA-vaccination: Practice changer of the…

A. Hausschild, P. Ascierto, D. Schadendorf, A. Arance, R. Dummer, C. Gebhart, G. Long, C. Robert

ENG

EBIN

ASCO 2024

Is the induction treatment the new strategy for…

A. Hausschild, P. Ascierto, D. Schadendorf, A. Arance, R. Dummer, C. Gebhart, G. Long, C. Robert

ENG

NADINA

ASCO 2024

Is adjuvant treatment still standard in macroscopic,…

A. Hausschild, P. Ascierto, D. Schadendorf, A. Arance, R. Dummer, C. Gebhart, G. Long, C. Robert

ENG

RELATIVITY-048

ASCO 2024

Is the triplet ready for phase 3?

A.Hausschild, P. Ascierto, D. Schadendorf, A. Arance, C. Gebhart, G. Long, C. Robert

ENG

PIVOTAL

ASCO 2024

Stimulating new combination of two antibody-cytokine…

A. Hausschild, P. Ascierto, D. Schadendorf, A. Arance, R. Dummer, C. Gebhart, G. Long, C. Robert

ENG

COMBI-AD

ASCO 2024

10 years follow up - immunotherapy for BRAF-mutated…

A. Hausschild, P. Ascierto, D. Schadendorf, A. Arance, R. Dummer, C. Gebhart, G. Long, C. Robert

Melanoma - 100 sec

ENG

KEYNOTE-942

ASCO 2024

mRNA vaccine plus pembrolizumab in adjuvant therapy

Axel Hauschild, MD

ENG

Relativity-048

ASCO 2024

Promising Results: Triple combination therapy in…

Paolo A. Ascierto, MD

ENG

KEYNOTE-942

ASCO 2024

3-year update on mRNA vaccines in melanoma

Dirk Schadendorf, MD

ENG

ASCO 2024

Impactful studies from ASCO 24 III: Cell-therapy

Georgina Long, MD

ENG

IOV-COM-202

ASCO 2024

TIL therapy for metastatic melanoma

Christoffer Gebhardt, MD

ENG

ASCO 2024

Lentigo maligna therapy

Reinhard Dummer, MD

ENG

EBIN

ASCO 2024

No differences in PFS between the two study arms

Ana Maria Arance, MD

ENG

NADINA

ASCO 2024

Consolidation of the use of IO in clinically detectable…

Ana Maria Arance, MD

ENG

COMBI-AD

ASCO 2024

Longterm survival after adjuvant targeted therapy

Reinhard Dummer, MD

ENG

PIVOTAL

ASCO 2024

Neoadjuvant intratumoral therapy with Daromun in…

Axel Hauschild, MD

ENG

ASCO 2024

Identifying patients with longterm benefits during…

Reinhard Dummer, MD

ENG

PIVOTAL

ASCO 2024

Intralesional therapy with Daromun

Dirk Schadendorf, MD

ENG

REALTIVIY-048

ASCO 2024

A new triplet for metastatic melanoma

Reinhard Dummer, MD

ENG

TRICOTEL

ASCO 2024

A new therapy benchmark for brain-met melanoma patients

Reinhard Dummer, MD

ENG

IGNYTE

ASCO 2024

Vaccine in combination with nivolumab for PDL1…

Axel Hauschild, MD

ENG

NADINA

ASCO 2024

Impactful studies from ASCO 24 I: NADINA

Georgina Long, MD

ENG

COMBI-AD

ASCO 2024

Adjuvant therapy with dabrafenib and trametinib - final…

Axel Hauschild, MD

ENG

NADINA

ASCO 2024

Neoadjuvant immunotherapy treatment for melanoma

Christoffer Gebhardt, MD

ENG

KEYMAKER-U02A

ASCO 2024

Emerging rescue therapies for PD1 refractory melanoma

Reinhard Dummer, MD

ENG

ASCO 2024

Promising activity of brenetafusp in PD-L1 refractory…

Ana Maria Arance, MD

ENG

RELATIVITY-048

ASCO 2024

Triple checkpoint blockade - a new approach?

Dirk Schadendorf, MD

ENG

COMBI-AD

ASCO 2024

Impactful studies from ASCO 24 II: Combi-AD

Georgina Long, MD

ENG

IGNYTE

ASCO 2024

New oncolytic immunotherapy (RP1) after PD-1 failure

Dirk Schadendorf, MD

ENG

COMBI-AD

ASCO 2024

Survival data for TT with dabrafenib and trametinib

Dirk Schadendorf, MD

ENG

NADINA

ASCO 2024

Progress in neoadjuvant therapy with IO

Dirk Schadendorf, MD

Melanoma - 100 sec

ESP

EBIN

ASCO 2024

No hubo diferencias en la PFS entre los dos brazos del…

Ana Maria Arance, MD

ESP

ASCO 2024

Prometedora actividad de brenetafusp en melanoma…

Ana Maria Arance, MD

ESP

NADINA

ASCO 2024

Consolidación del uso de IO en melanoma en estadio III…

Ana Maria Arance, MD

ITA

Relativity-048

ASCO 2024

Risultati promettenti: Tripla terapia di combinazione…

Paolo A. Ascierto, MD

Miscellaneous

ASCO 2024

New therapeutic approaches: Get over PD1 resistances?

Philipp Ivanyi, MD

ENG

ASCO 2024

Encouraging developmental IO-options

Hans Hammers, MD, PhD

Gynecologic Cancer

ENG

BrUOG 354

ASCO 2024

Clear cell carcinomas benefit from IO therapy

Diana Lüftner, MD

ENG

KEYVIBE-005

ASCO 2024

New idea: anti-digest for EC?

Diana Lüftner, MD

ENG

NEO

ASCO 2024

De-escalation in ovarian cancer?

Diana Lüftner, MD